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Human Tra2 Proteins Are Sequence-Specific
Activators of Pre-mRNA Splicing
and Baker, 1995; Lynch and Maniatis, 1996). SR proteins
(for review, Manley and Tacke, 1996; ValcaÂ rcel and
Green, 1996) and Tra2, which contain RNP-type RNA-
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binding domains (RBD), together with Tra are part of aColumbia University
superfamily of proteins characterized by domains richNew York, New York 10027
in arginine/serine dipeptide repeats (RS domain) (for²Department of Anatomy and Neuroscience
review, Fu, 1995). RS domains can participate in specificOsaka University Medical School
protein±protein interactions (Amrein et al., 1994; Kohtz2-1 Yamadaoka
et al., 1994; Xiao and Manley, 1997) and are generallySuita, 565
phosphorylated in vivo (Gui et al., 1994; Colwill et al.,Japan
1996). Tra2 contains a single RBD flanked by two RS
domains (Amrein et al., 1988; Goralski et al., 1989),
whereas SR proteins contain one or two N-terminalSummary
RBDs and a C-terminal RS domain.
While the Drosophila sex-determination cascade il-The RNA-binding protein Tra2 is an important regula-
lustrates that alternative splicing can result in strictlytor of sex determination in Drosophila. Recently, two
stage-specific expression patterns, splicing patterns ofmammalian Tra2 homologs of unknown function have
mammalian genes are often complex, and tissue- orbeen described. Here, we show that human Tra2 pro-
stage-specific variations seem less pronounced. Per-teins are present in HeLa cell nuclear extracts and that
haps because of this complexity, it has been difficultthey bind efficiently and specifically to a previously
to identify mammalian factors involved in the tissue-characterized pre-mRNA splicing enhancer element.
specific control of single splicing events. A number ofIndeed, both purified proteins bound preferentially to
observations, however, suggest that SR proteins mayRNA sequences containing GAA repeats, characteris-
participate in the maintenance and regulation of cell-tic of many enhancer elements. Neither Tra2 protein
specific splicing patterns. SR proteins are constitutivefunctioned in constitutive splicing in vitro, but both
components of the splicing machinery that play impor-activated enhancer-dependent splicing in asequence-
tant roles during spliceosome assembly by promotingspecific manner and restored it after inhibition with
splice site recognition (Crispino et al., 1994; Kohtz et al.,competitor RNA. Our findings indicate that mamma-
1994; Tarn and Steitz, 1994) and facilitating interactionslian Tra2 proteins are sequence-specific splicing acti-
between 59 and 39 splice site complexes (Wu and Ma-vators that likely participate in the control of cell-spe-
niatis, 1993; TroncheÁ re et al., 1997). Individual SR pro-cific splicing patterns.
teins are able to complement splicing-deficient cyto-
plasmic S100 extracts, which lack SR proteins butIntroduction
contain other factors necessary for constitutive splicing
(e.g., Ge et al., 1991; Krainer et al., 1991; Zahler et al.,
Extraordinary examples of how alternative splicing can
1992). In addition, SR proteins can influence alternative
control eukaryotic gene expression are provided by the
splicing in a concentration-dependent manner, either
central steps in the regulatory cascade that determines
when added to splicing-competent nuclear extracts
sex-specific somatic differentiation in Drosophila mela-
(e.g., Ge et al., 1991; Krainer et al., 1991; Zahler et al.,
nogaster (for review, Burtis, 1993). In this cascade, fe-
1993) or when transiently overexpressed in vivo (e.g.,
male-specific expression of the transformer gene prod- CaÂ ceres et al., 1994; Screaton et al., 1995; Wang and
uct Tra is accomplished by blockage of the strong
Manley, 1995). SR proteins have also been shown to
default 39 splice site by the female-specific Sex-lethal
participate in splicing activation of introns containing
protein. The resulting utilization of the weaker female-
weak 59 or 39 splice sitesby binding to purine-richexonic
specific 39 splice site is required for expression of a splicing enhancers (ESE), frequently situated in down-
functional Tra protein (ValcaÂ rcel et al., 1993). Tra in turn stream exons (Lavigueur et al., 1993; Sun et al., 1993;
cooperates with the non±sex-specific protein Tra2 (the Staknis and Reed, 1994; Ramchatesingh et al., 1995;
transformer-2 gene product) to promote inclusion of the Yeakley et al., 1996). Conversely, high-affinity binding
female-specific exon 4 into the doublesex (dsx) mRNA sites for the SR proteins ASF/SF2 (Tacke and Manley,
(Hoshijima et al., 1991; Tian and Maniatis, 1992). Exon 1995) and SRp40 (Tacke et al., 1997) have been demon-
4 is associated with a weak 39 splice site that is not strated to function as ESEs in vitro. These and other
used in male flies and contains a positive regulatory studies (Fu, 1993; Chandler et al., 1997) also showed
sequence, the so-called dsx enhancer, which consists that SR proteins have distinct RNA binding specificities
of six 13-nucleotide repeats and a purine-rich element and display substrate specificity in vitro.
(Lynch and Maniatis, 1995). Tra and Tra2 bind coopera- Unlike SR proteins, one of which, B52, has been
tively to the enhancer to which they recruit members of shown to be required for development in Drosophila
the SR protein family of general splicing factors (Inoue (Ring and Lis, 1994; Peng and Mount, 1995) and another,
et al., 1992; Tian and Maniatis, 1993, 1994; Heinrichs ASF/SF2, for viability of chicken DT40 cells (Wang et
al., 1996), Drosophila Tra2 is apparently nonessential.
Chromosomally female flies that are homozygous for a³To whom correspondence should be addressed.
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loss-of-function mutation in transformer-2 are trans-
formed into sterile phenotypical males but otherwise
develop normally (Baker and Ridge, 1980). Tra2, to-
gether with Tra, regulates not only dsx pre-mRNA splic-
ing but also sex-specific expression of the fruitless gene
(Heinrichs et al., 1998), which controls sexual orientation
and courtship behavior (Ryner et al., 1996). In addition,
Tra2 is required for spermatogenesis in the male germ
line, where it influences pre-mRNA processing in a Tra-
independent manner (Mattox and Baker, 1991; Amrein
et al., 1994; Hazelrigg and Tu, 1994; Madigan et al., 1996;
Mattox et al., 1996). No functions of Tra2 outside sexual
differentiation have so far been discovered in Drosoph-
ila. Recently, two human homologs of Tra2, Tra2a (Dau-
walder et al., 1996) and Tra2b (Beil et al., 1997), have
been identified. Using transgenic flies with nonfunc-
tional Tra2, Dauwalder et al. (1996) demonstrated that
human Tra2a is able to rescue Tra-dependent but not
Tra-independent functions. The natural functions of Figure 1. A 40 kDa SR Protein Binds Specifically to the A3 Enhancer
mammalian Tra2proteins are, however, unknown, as are NE proteins bound to biotinylated A3 (lane 1) or S3 (lane 2) RNA
their RNA binding specificities. Since the mechanisms of were resolved by 9% SDS/PAGE and analyzed by Western blot with
mAb104. Twenty-five percent of bound material is shown. Fractionssexual differentiation are not conserved between mam-
(2%) of unbound material are shown in lanes 3 and 4.mals and flies, it is possible that human Tra2 proteins
serve more general purposes than their Drosophila ho-
molog.
SF2, a nuclear fraction, NF20-40, was also requiredPreviously, we reported the creation of a purine-rich
(Tacke and Manley, 1995). To investigate further theESE, A3, which consists of three copies of a high-affinity
interaction of the enhancer with SR proteins, we usedASF/SF2-binding site (Tacke and Manley, 1995). Here,
an in vitro selection assay in which biotinylated A3 orwe report the unexpected identification of a HeLa cell
S3 RNA was incubated in NE under splicing conditions,nuclear protein that binds specifically to A3 as one or
recovered with avidin agarose, and the bound proteinsboth of the human Tra2 proteins. Using SELEX (Tuerk
then analyzed by Western blots with the monoclonaland Gold, 1990) and gel mobility-shift experiments, we
antibody mAb104, which recognizes a phosphoepitopefind that Tra2a and Tra2b have indistinguishable RNA
in RS domains (Roth et al., 1991). Surprisingly, a 40 kDabinding specificities and bind preferentially to oligo
protein rather than ASF/SF2 was the predominant SR(GAA) sequences, such as are present in A3 and several
protein (i.e., a protein recognized by mAb104) selectednatural splicing enhancers (e.g., Lavigueur et al., 1993;
by A3 (Figure 1, lane 1). Binding to A3 was specific, asXu et al., 1993; Yeakley et al., 1993). Splicing assays
no binding to S3 could be detected (Figure 1, lane 2),with HeLa S100 extracts, which lack Tra2 proteins, indi-
suggesting that this protein might play an important rolecate that they are not required for constitutive splicing
in A3-dependent splicing.and cannot replace the essential splicing functions of
To test whether the 40 kDa protein selected by A3SR proteins. However, both Tra2 proteins can activate
was the SR protein SRp40, we took advantage of poly-A3-dependent splicing in a sequence-specific manner
clonal anti-SRp40 antibodies and the fact that SRp40when added to limiting amounts of HeLa nuclear ex-
can be selected from NE by its genuine high-affinitytracts and can restore enhancer-dependent splicing that
binding site, B1 (Tacke et al., 1997). As shown in Figurehad been inhibited by excess A3 competitor RNA. To-
2, mAb104 generated signals of similar intensities withgether, our data indicate that Tra2a and Tra2b are se-
the 40 kDa protein selected by A3 (lane 2), authenticquence-specific activators of pre-mRNA splicing. The
SRp40 selected by B1 (lane 4), and 60 ng of baculovirus-Tra2 proteins are the first mammalian proteins identified
produced SRp40 (lane 6). Recognition by mAb104 wascapable of functioning in this manner that are not also
abolished in each case by treatment of the samplesessential splicing factors, and they thus are likely to play
with alkaline phosphatase (CIP) before Western analysisimportant roles in splicing control.
(Figure 2, lanes 3, 5, and 7). In contrast, anti-SRp40
antibodies recognized the B1-selected protein (FigureResults
2, lane 10) and baculovirus-produced SRp40 (Figure 2,
lane 12) but not the A3-selected protein (Figure 2, laneA 40 kDa SR Protein in HeLa Nuclear Extracts
8). Identical results were obtained with the CIP-treatedBinds Specifically to the A3 Enhancer
samples (Figure 2, lanes 9, 11, and 13). Note thatUsing UV cross-linking assays, we showed previously
mAb104 and anti-SRp40 antibodies also recognized anthat ASF/SF2 bound specifically to the A3 splicing en-
unidentified SRp30 protein selected by B1 (Figure 2,hancer in HeLa nuclear extracts (NE) but not to a similar
lanes 4, 10 and 11), as previously reported (Tacke etpurine-rich sequence, S3, that did not function as an
al., 1997). Our results strongly suggest that the 40 kDaenhancer. Furthermore, our data indicated that ASF/SF2
protein binding to A3 is not SRp40. This conclusion waswas necessary but not sufficient for activation of A3-
dependent splicing in S100 extracts. In addition to ASF/ corroborated by selection experiments with the nuclear
Activation of Pre-mRNA Splicing by Human Tra2
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Figure 3. A Human Tra2 Protein Is Recognized by mAb104 and
Binds Specifically to A3
(A) NE proteins bound to biotinylated A3 or S3 RNA were analyzed
by Western blot with anti-Tra2 antibodies (lanes 1±4) or mAb104
(lanes 5±8) before (2) or after (1) treatment with CIP. As a result of
partial dephosphorylation in this experiment, CIP treatment did not
abolish recognition by mAb104 but enhanced mobility of the recog-
nized proteins.Figure 2. The A3-Binding 40 kDa Protein Is Not SRp40
(B) Western analysis with anti-Tra2b-antibodies of S100 (lane 1), NEShown are Western blots with mAb104 (left) and anti-SRp40 anti-
(lane 2), NF20-40 (lane 3), and NE proteins selected by A3 (lane 4)bodies (right) of NE proteins bound to biotinylated A3 (lanes 2, 3,
or S3 (lane 5).8, and 9) or B1 RNA (lanes 4, 5, 10, and 11) and of 60 ng purified
SRp40 (lanes 6, 7, 12, and 13). Samples were either untreated (2)
or treated with CIP (1), which abolished recognition by mAb104.
Lane 1, fraction of input material. Note that B1 binds an unidentified As shown in Figure 3A, a 40 kDa protein selected from
30 kDa SR protein in addition to SRp40.
NE specifically by A3 (lane 2) but not S3 (lane 1) was
detected with the antibodies. This protein comigrated
with the A3-binding protein identified by mAb104 (lane
fraction NF20-40. A 40 kDa protein was selected by A3 6). CIP treatment of the samples enhanced recognition
but not by B1, indicating that NF20-40 contains the A3- by the anti-HTra2 antibodies (lane 4) and, in addition,
binding protein but not SRp40 (data not shown). resulted in equivalent mobility-shifts of the proteins rec-
ognized by the two different antibodies (compare lanes
4 and 8), confirming that the proteins are indeed identi-
cal. We conclude that one or both of the human Tra2The A3-Binding Protein Recognized by mAb104
proteins bind specifically to the A3 enhancer.Is a Tra2 Protein
We next wished to determine the distribution of Tra2What is the identity of the A3-binding protein? Recent
in various subcellular fractions, as this could providecloning of two mammalian homologs of the Drosophila
some insight into the possible function of the proteins.splicing regulator Tra2, Tra2a (Dauwalder et al., 1996)
However, because of the low affinity of the anti-Tra2and Tra2b (Matsuo et al., 1995; Segade et al., 1996;
antibodies to phosphorylated Tra2 proteins, a highlyBeil et al., 1997), revealed that both proteins are highly
specific anti-Tra2b antibody (see Experimental Proce-homologous RS domain proteins with extended stretches
dures) was used to address this question. As shown inof RS dipeptide repeats, especially in their N-terminal
Figure 3B, Tra2b was not detected in S100 (lane 1) butRS domains. Moreover, SRp40, Tra2a, and Tra2b all
was readily detected in both NE (lane 2) and NF20-40have very similar predicted molecular weights and
(lane 3). In addition, Tra2b was selected by A3 but notamounts of R and S residues. We therefore reasoned
S3 from NE (lanes 4 and 5) or NF20-40 (data not shown).that phosphorylated human Tra2 proteins, if present in
These results confirm that Tra2b can interact specificallyHeLa cells, might be recognized by mAb104 and display
with a splicing enhancer, and its presence in NF20-40migration properties similar to SRp40 in SDS/polyacryl-
but not S100 is consistent with a possible role in theamide gels. To test whether phosphorylated Tra2 pro-
function of such elements.teins are recognized by mAb104, His-tagged versions
of both proteins (HTra2a and HTra2b) were expressed in
and purified from Escherichia coli. Indeed, both HTra2a RNA Binding Specificities of Human
Tra2a and Tra2band HTra2b, which were not recognized by mAb104 in
their unphosphorylated states, reacted strongly with the How do the Tra2 proteins bind to the A3 enhancer? One
possibility is that they fortuitously recognize an RNAantibody either after incubation under splicing condi-
tions in NE or S100 or following phosphorylation by the sequence similar to the ASF/SF2 recognition motif pres-
ent in A3. Alternatively, they could be recruited to theSR protein kinase Clk/Sty (data not shown).
To determine whether the A3-binding protein recog- enhancer not by direct RNA binding but by interaction
with other proteins (e.g., ASF/SF2), which would be con-nized by mAb104 was in fact a Tra2 protein, we raised
polyclonal antibodiesagainst HTra2a. The resulting anti- sistent with their preferential detection by biotin selec-
tion as opposed to UV cross-linking. To distinguish be-bodies recognized both HTra2a and HTra2b, owing to
the high degree of sequence identity between the two tween these possibilities, we decided to ascertain the
RNA binding specificities of both proteins and to deter-proteins, but not recombinant SRp40 or proteins present
in a standard SR protein preparation (data not shown). mine whether these would be consistent with the idea
Cell
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was observed with all sequences containing either
poly(A) or oligo(GAA) but not with R17. Notably, binding
was also observed with the sequence A7, containing
the ASF/SF2-binding site AGAAGAAC, three copies of
which constitute the A3 enhancer.
Unlike oligo(GAA), poly(A) appears to be unable to
function as a splicing enhancer (Tanaka et al., 1994),
and attempts to recover Tra2 proteins from NE with
biotinylated poly(A) RNA were unsuccessful (data not
shown). This raises the possibility that authentic Tra2
proteins might not recognize poly(A). To obtain a recom-
binant Tra2 protein that resembled the authentic protein
as closely as possible, untagged Tra2a (Tra2a) was ex-
pressed in baculovirus-infected insect cells and purified
by classical biochemical methods (see Experimental
Procedures). As shown in Figure 4C, this protein bound
efficiently to oligo(GAA)-containing sequences (A7, R21,
R22) but poorly to the poly(A)-containing sequence T12.
We also attempted to purify untagged Tra2b from bacu-
lovirus-infected insect cells, but for technical reasons
only a fraction enriched in Tra2b could be prepared (see
Experimental Procedures). Therefore, a fusion protein
Figure 4. RNA Binding Specificities of Tra2a and Tra2b
of glutathione-S transferase and Tra2b was expressed
(A) Sequences selected by Tra2b after five rounds of SELEX (R1-
in and purified from E. coli, phosphorylated in HeLaS100R24). A7 and T12 represent sequences selected by ASF/SF2 and
extracts, and repurified (GST-Tra2b). Similar to Tra2a,Tra2a, respectively. Poly(A) sequences are in boldface; GAA motifs
GST-Tra2b bound efficiently only to the oligo(GAA)-con-are in italicized boldface.
(B) Gel mobility-shift assays of the indicated radiolabeled sequences taining sequences (A7, R21, and R22) (Figure 4D).
were performed with increasing concentrations (3, 15, and 75 nM) Hence, we conclude that Tra2a and Tra2b have very
of HTra2a. similar RNA binding specificities, binding preferentially
(C) and (D) Gel mobility-shift assays with 1.2, 6, and 30 nM of bacu-
to oligo(GAA)-containing sequences. We do not knowlovirus-produced Tra2a (C) or with 2, 10, and 50 nM of bacterially
the reason for selection of poly(A) sequences by SELEXproduced GST-Tra2b (D).
but suspect that it may reflect the presence of the His-
tag on the recombinant proteins used in this assay.
that the proteins bind directly to A3 and perhaps other
purine-rich splicing enhancers. To this end, we first per-
formed SELEX with HTra2a and HTra2b that had been Tra2a and Tra2b Stimulate A3-Dependent Splicing
but Cannot Substitute for the Essentialphosphorylated in vitro by Clk/Sty (Tacke et al., 1997).
Selected sequences were inspected after five cycles Splicing Function of SR Proteins
Taken together, our results provide evidence that bothof selection and amplification. Unexpectedly, all of 20
sequences selected by HTra2a contained extended Tra2a and Tra2b can bind directly to A3 and possibly
other purine-rich splicing enhancers. What is the func-stretches of poly(A). In one case, the entire selected
sequence consisted of a continuous poly(A) sequence tional significance of this, and how, if at all, do Tra2
proteins function in splicing? An important feature ofof 24 adenosine residues (data not shown). Sequences
selected by HTra2b showed greater variety (Figure 4A). SR proteins is that any one of them is sufficient to com-
plement splicing-deficient S100 extracts for splicing ofAlthoughmany of themalso containedstretchesofpoly(A),
others contained motifs of oligo(GAA), which, remark- at least some substrates containing consensus or near-
consensus splice sites. Based largely on this feature,ably, are also found in A3 and a number of naturally
occurring splicing enhancers (e.g., Lavigueur et al., SR proteins have been termed general, essential, or
constitutivesplicing factors and are thought tobe redun-1993; Xu et al., 1993; Yeakley et al., 1993).
To test the significance of these sequences as binding dant in this assay. We first sought to determine whether
Tra2 proteins might have similar functions. Significantly,sites for HTra2a and HTra2b, we performed gel mobility-
shift experiments with both proteins. Since no signifi- both Tra2a (Figure 5A, lanes 4 and 5) and GST-Tra2b
(data not shown) were unable to activate splicing of acant differences were found between the binding speci-
ficities of the two proteins (data not shown), the findings b-globin pre-mRNA in S100, although efficient splicing
was observed with ASF/SF2 (Figure 5A, lanes 2 and 3).are exemplified in Figure 4B by an experiment with
HTra2a. Four oligo(GAA)-containing sequences, three Identical results were obtained with PiP7A RNA (Kohtz
et al., 1994) as a substrate (data not shown). We nextof which were selected by HTra2b (R15, R21, and R22)
and one by a truncated version of ASF/SF2 (A7; Tacke tested whether Tra2a or Tra2b was able to complement
S100 for splicing of a pre-mRNA containing the A3 en-and Manley, 1995); a poly(A)-containing sequence se-
lected by HTra2a (T12); and an HTra2b-selected se- hancer. As a splicing substrate, we used an IgM-based
pre-mRNA with a suboptimal pyrimidine tract (Watakabequence containing neither poly(A) nor oligo(GAA) (R17)
were radiolabeled and incubated with 3, 15, or 75 nM et al., 1993) containing the A3 enhancer downstream of
the 39 splice site (M-A3; see Experimental Procedures).of phosphorylated, repurified HTra2a. Efficient binding
Activation of Pre-mRNA Splicing by Human Tra2
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Figure 5. Tra2 Proteins Cannot Substitute for Essential Splicing
Figure 6. Tra2 Proteins Specifically Stimulate A3-DependentFunctions of SR Proteins
Splicing
In vitro splicing of b-globin (A) and M-A3 (B) pre-mRNAs in S100
In vitro splicing of M-A3 (A) or M-B3 (B) in NE (lane 1) or limitingsupplemented with no additional protein (lane 1) or purified proteins
amounts of NE supplemented with no protein (lane 2), Tra2a (laneas indicated.
3), a fraction enriched in Tra2b (lane 4), or individual SR proteins as(A) Efficient splicing of b-globin with 60 (lane 2) or 120 (lane 3) nM
indicated (lanes 5±7). Recombinant purified proteins were used atASF/SF2; no splicing with 60 (lane 4) or 120 (lane 5) nM Tra2a. (B)
120 nM in all reactions.Efficient splicing of M-A3 with 1 mg/assay of purified SR proteins
(lane 2) or 600 nM ASF/SF2 (lane 5); no splicing with 360 nM Tra2a
(lane 3), 360 nM phosphorylated GST-Tra2b (lane 4), or 600 nM SC35
et al., 1997), which does not bind the Tra2 proteins, in(lane 6).
place of A3 will not respond to Tra2. Indeed, neither
Tra2a nor Tra2b activated splicing of M-B3 in limiting
amounts of NE (Figure 6B, lanes 3 and 4). In contrast,As shown in Figure 5B, SR proteins purified from HeLa
stimulation was again observed with the SR proteins,cells (lane 2) and ASF/SF2 (lane 5) were active in this
although in this case it was very slight with ASF/SF2assay, although high concentrations (1 mg/assay of SR
(Figure 6B, lanes 5±7; activation likely reflects coopera-proteins or 600 nM ASF/SF2) were required for efficient
tion with SRp40 present in NE). Hence, sequence-spe-splicing. In addition, ASF/SF2 produced unidentified
cific binding of Tra2 to A3 likely plays a role in the activa-bands, probably reflecting aberrant splice site and/or
tion of A3-dependent splicing in NE.branch point usage (lane 5). In contrast to ASF/SF2,
To extend the above results, we performed competi-Tra2a (lane 3) and GST-Tra2b (lane 4) were inactive. As
tion assays in NE, using as competitors the A3, B3, andexpected, SC35, which binds the A3 enhancer poorly
S3 sequences. As shown in Figure 7A, 5-fold excess(Tacke and Manley, 1995), was also inactive (lane 6). We
of A3 decreased the splicing efficiency of M-A3 in NEconclude that Tra2 proteins cannot carry out essential
dramatically (lane 2), while 15-fold excess of B3 had nosplicing functions executed by SR proteins, neither with
effect (lane 5). S3, which does not function as an en-consensus-type substrates nor with a pre-mRNA con-
hancer (Tacke and Manley, 1995), also had no effect as ataining an enhancer with high-affinity binding sites for
competitor (Figure 7A, lanes 6 and 7). Most importantly,Tra2 proteins.
inhibition of A3-dependent splicing by A3 competitorThe above results indicate that the human Tra2 homo-
logs, in the absence of SR proteins, are unable to acti-
vate enhancer-dependent splicing. However, these find-
ings do not address the possibility that one or both of
these proteins might nonetheless play an important role
in enhancer-dependent splicing under more physiologi-
cal conditions. Therefore, we employed an assay in
which limiting amounts of NE (e.g., Yeakley et al., 1996)
that promoted very little if any splicing of M-A3 were
supplemented with Tra2b, purified Tra2a, or different
SR proteins. Most importantly, both Tra2a and Tra2b
Figure 7. Tra2 Proteins Restore M-A3 Splicing Inhibited by Ex-
significantly enhanced M-A3 splicing (Figure 6A, lanes cess A3
3 and 4). The SR proteins tested were also active in
(A) Splicing of M-A3 in NE is inhibited by 5-fold (lanes 2, 4, and 6)
this assay, but stimulation was reduced, especially with or 15-fold (lanes 3, 5, and 7) molar excess of A3, but not B3 or S3.
SC35 (Figure 6A, lanes 5±7). Stimulation by SR proteins Lane 1, no competitor.
(B) Sixty or 120 nM Tra2a (lanes 3 and 4), 60 or 120 nM phosphory-may partly reflect general splicing functions that are
lated GST-Tra2b (lanes 5 and 6), or a combination (60 nM each) ofindependent of the enhancer. However, Tra2 proteins
both (lane 7) restore M-A3 splicing inhibited by a 10-fold excessare unable to carry out such functions (see above). Thus,
of A3.stimulation of M-A3 splicing by Tra2 proteins likely de-
(C) Sixty or 240 nM ASF/SF2 (lanes 3 and 4), but not SC35 (lanes 5
pends upon their ability to bind to the A3 enhancer. A and 6), partially restores splicing inhibited by 10-fold excess of A3
prediction from this is that a related substrate, M-B3, but less effectively than 30 or 120 nM GST-Tra2b (b) (lanes 7 and
8). Only the splicing substrates and mRNA products are shown.containing the SRp40-dependent B3 enhancer (Tacke
Cell
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RNA could be relieved by Tra2a (Figure 7B, lanes 3 and properties of the proteins. In fact, changing the labeled
base from G to A strongly increased the cross-linking4), GST-Tra2b (Figure 7B, lanes 5 and 6; Figure 7C, lanes
7 and 8), or a combination of both (Figure 7B, lane 7). efficiency of Tra2 proteins compared to ASF/SF2 (R. T.
and J. L. M., unpublished data), confirming the high-Depending on the experiment, 30±120 nM of GST-Tra2b
was sufficient to restore 50%±100% of the splicing effi- affinity of Tra2 for A3and also indicating that the proteins
recognize the A3 sequence in different ways. The latterciency obtained in the absence of competitor RNA. ASF/
SF2 was able to partially restore M-A3 splicing inhibited may be expected, as Tra2 and ASF/SF2 differ in the
number of RNA-binding domains they contain (one andby A3 (Figure 7C, lanes 3 and 4) butwas significantly less
effective than the Tra2 proteins. For example, splicing two, respectively) and do not share significant homology
with each other in the RNA-binding regions. This makesefficiencies were similar with 240 nM ASF/SF2 and 30
nM GST-Tra2b (Figure 7C, compare lanes 4 and 7). SC35 it all the more remarkable that these two splicing factors
with related but clearly distinct functions and propertiesdid not restore splicing and in fact further decreased
splicing efficiency at higher concentrations (Figure 7C, recognize very similar RNA sequences.
The physiological significance of the related RNAlanes 5 and 6). Together, our results demonstrate that
Tra2 proteins can specifically activate A3-dependent binding specificities of ASF/SF2 and Tra2 proteins re-
mains to be determined. However, a previous analysissplicing, likely reflecting theirability tobind theenhancer
with high affinity. of the dsx enhancer is consistent with the possibility that
ASF/SF2 and Drosophila Tra2 also possess overlapping
RNA binding specificities. Both proteins were shown toDiscussion
bind the dsx enhancer with 4- to5-fold lower efficiencies
when an 18-base purine-rich element (PRE) was deletedIn this paper, we have shown that the human homologs
(Lynch and Maniatis, 1995). The two proteins also boundof the Drosophila Tra2 protein are present in HeLa nu-
the isolated PRE, with Drosophila Tra2 showing the high-clear extract and, unexpectedly, bind efficiently to a
est specificity for this sequence, despite the fact thatsplicing enhancer consisting of high-affinity binding
the PRE lacks a GAA triplet. Whether this reflects thesites for the SR protein ASF/SF2. Both Tra2 proteins
fact that the PRE is a low-affinity Tra2-binding site orbound tightly and specifically to RNA sequences con-
is indicative of a slight difference in binding specificitytaining GAA repeats, which are similar both to the ASF/
between Drosophila and human Tra2 proteins is notSF2 consensus recognition motif and to sequences
known. The human and Drosophila Tra2 RBDs are 54%found in a number of naturally occurring splicing en-
identical.hancers. We have provided evidence that the Tra2 pro-
teins are not required for constitutive splicing but in-
Tra2 Proteins as Mammalian Splicing Regulatorsstead play an important role in enhancer-mediated
Unlike SR proteins, Tra2 proteins appear not to functionactivation of splicing. Thus, the Tra2 proteins on the one
as constitutive splicing factors despite their overallhand appear to play a more restricted role in splicing
structural similarities to SR proteins. SR proteins pos-than do the structurally related SR proteins, while on
sess distinct RNA binding specificities (e.g., Heinrichsthe other hand they display properties indicative of a
and Baker, 1995; Tacke and Manley, 1995; Tacke et al.,critical function in splicing control.
1997), and their RS domains function redundantly in
certain assays in vitro (Chandler et al., 1997) and are
RNA Binding Specificities of Tra2 Proteins entirely interchangeable in vivo (J. Wang and J. L. M.,
Our data suggest that human Tra2 proteins and the SR submitted). This suggests that neither the RNA binding
protein ASF/SF2 have overlapping RNA binding speci- specificity nor the nature of the RS domain is a decisive
ficities. Both Tra2a and GST-Tra2b recognized the se- determinant for constitutive splicing activity. In fact, via-
quence A7, which was previously obtained by SELEX bility of DT40 cells genetically depleted of ASF/SF2 can
with a truncated version of ASF/SF2 lacking its RS do- be rescued by chimeric ASF/SF2 proteins in which the
main. A7 contains a perfect match of the ASF/SF2 con- genuine RS domain was replaced by either the N- or
sensus octamer AGAAGAAC and constitutes a high- C-terminal RS domain of Tra2a (J. Wang and J. L. M.,
affinity binding site for authentic ASF/SF2 (Tacke and submitted), indicating that both Tra2a RS domains can
Manley, 1995). Based on gel-shift assays with A7, we perform the essential functions of the ASF/SF2 RS do-
estimate that ASF/SF2 and Tra2a bind this sequence main. It is, however, possible that the overall domain
with similar affinities (i.e., with apparent KD values of organization of Tra2 proteins, which differs from that
approximately 50 and 30 nM, respectively). Surprisingly, of SR proteins, is incompatible with a function as a
binding of Tra2 proteins present in NE to biotinylated constitutive splicing factor, perhaps by preventing cru-
A3 could be readily detected, while binding of ASF/SF2 cial protein±protein interactions with other essential
was weak. In contrast, UV cross-linking assays using splicing factors, such as the U1 snRNP 70 kDa protein
A3 with radioactively labeled G nucleotides initially sug- or U2AF (Wu and Maniatis, 1993; Kohtz et al., 1994; Zuo
gested that ASF/SF2 bound A3 more efficiently than and Maniatis, 1996). In addition, Tra2 and SR proteins
other nuclear proteins, in particular more efficiently than may differ in the way they position themselves on the
a 40 kDa protein that likely represented a Tra2 protein RNA. In this context, it is noteworthy that despite their
but was previously considered to be SRp40 (Tacke and differences in RNA binding specificities, SR proteins
Manley, 1995). This discrepancy may reflect the different possess common motifs in their RNA-binding domains,
properties of the two assays, different cross-linking effi- which are characteristic of the family (Birney et al., 1993)
but are not shared with Tra2 proteins.ciencies of the two proteins, and/or different binding
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Unlike M-A3 pre-mRNA, which could be spliced in than ASF/SF2. Thus, in the case of natural enhancers
that appear to contain high-affinity Tra2 binding sitesS100 with purified SR proteins or ASF/SF2 alone, splic-
ing of another A3-enhancer substrate, GN-A3, required (e.g., Lavigueur et al., 1993; Xu et al., 1993; Yeakley et
al., 1993; Ryan and Cooper, 1996; Elrick et al., 1998),in addition the nuclear fraction NF20-40 (Tacke and
Manley, 1995). It is likely that part of the activity of NF20- the Tra2 proteins likely play important roles in the control
of enhancer-dependent splicing patterns in vivo, per-40 is due to the presence of Tra2 proteins in this fraction.
However, NF20-40 could not be replaced by Tra2 pro- haps by recruiting SR proteins or other factors to the
enhancer. Cooperative interactions between Drosophilateins and, in addition, is not essential for M-A3 splicing.
Additional factors in NF20-40 are therefore likely re- Tra2 and SR proteins have been documented (Lynch
and Maniatis, 1996), and there is also evidence thatquired by specific features of the GN-A3 substrate other
than the enhancer sequence itself. Notable among the human Tra2 proteins can interact with SR proteins (Beil
et al., 1997; Shin et al., unpublished data).differences between the GN-A3 and M-A3-substrates
are the closer proximity of the enhancer to the 39 splice What are the specific functions of the two Tra2 pro-
teins in vivo? Our data have not revealed functionalsite in M-A3 and the fact that M-A3 contains a weak 39
splice site, while GN-A3 contains a weak 59 splice site. differences between Tra2a and Tra2b. Their RBDs are
85% identical, consistent with our finding that their RNAPrevious studies showed that SR proteins present in
nuclear extracts bind to purine-rich ESEs (e.g., Lavi- binding specificities are indistinguishable. The proteins
differ mainly in the N-terminal 49 amino acids and in thegueur et al., 1993; Sun et al., 1993; Ramchatesingh et
al., 1995) and are present in enhancer complexes (Stak- position of a polyglycine stretch within their C-terminal
RS domains, which otherwise are highly homologous.nis and Reed, 1994). Identification of SR proteins has
mainly relied on their size and recognition by mAb104. One possibility consistent with our data is that the two
proteins are functionally redundant in vivo. Alternatively,Our data indicate that it may be difficult to distinguish
between human Tra2 proteins and SRp40 with mAb104. the small differences in primary structure may account
for potential differences in protein±protein interactions,Recently, Yeakley et al. (1996) reported specific binding
of a 40 kDa nuclear extract protein to an enhancer ele- including with constitutive splicing factors such as SR
proteins or with cell-specific factors yet to be discovered.ment consisting of an oligo(GAA)-containing sequence.
The authors identified the protein as SRp40 on the basis An important aspect of the function of the Drosophila
Tra protein in the regulation of dsx splicing appears toof its reactivity with mAb104, but they were unable to
detect binding of SRp40 when using purified SR pro- be its ability to influence the RNA binding properties
of Tra2 through cooperative interaction. Whereas Tra2teins. Based on these and additional findings, they con-
cluded that SRp40 was recruited to the enhancer by a binds preferentially to the purine-rich element of the dsx
enhancer in the absence of Tra, it can also bind to thecofactor or complex present in NE. In the light of our
data, it seems likely that the 40 kDa SR protein was one dsx repeats in the presence of Tra (Lynch and Maniatis,
1995, 1996). It is tempting to postulate a scenario inor both of the human Tra2 proteins rather than SRp40
and that it bound the oligo(GAA) element directly. This which cell-specific factors alter the RNA binding proper-
ties of human Tra2 proteins analogous to the Tra/Tra2conclusion is significant because it questions the view
that RBD-containing RS domain proteins can be re- cooperation in Drosophila. It is also noteworthy that
Tra2b was initially identified as a factor rapidly inducedcruited to splicing complexes independent of their RNA
binding activity. A 40 kDa protein in HeLa NE shown to during reoxygenation of astrocytes after hypoxia (Mat-
suo et al., 1995) and subsequently shown to displaybe cross-linked by UV to an oligo (GAA)-containing ESE
in the cardiac troponin T pre-mRNA probably also repre- different mRNA expression levels in various mouse tis-
sues (Segade et al., 1996). These examples raise thesents a human Tra2protein (Ramchatesingh et al., 1995).
Several studies have shown that SR proteins, includ- possibility that at least in some cases mammalian Tra2
proteins themselves might act as stage-specific regula-ing ASF/SF2 and SRp40, can participate in the activation
of ESE-dependent splicing in vitro (Sun et al., 1993; tors of pre-mRNA splicing. As in Drosophila, in vivo
genetic studies may ultimately be required to elucidateRamchatesingh et al., 1995; Tacke and Manley, 1995;
Yeakley et al., 1996; Tacke et al., 1997). Although in most the precise roles of mammalian Tra2 proteins in the
control of cell- and stage-specific splicing patterns.instances nuclear extracts containing Tra2 were used,
in one case SR proteins were shown to activate ESE-
dependent splicing in S100 extracts (Ramchatesingh et Experimental Procedures
al., 1995). This is consistent with our results and sug-
Constructsgests that human Tra2 proteins need not be absolutely
The cDNA for the coding region of human Tra2a was obtained asrequired for ESE-dependent splicing. How critical then
an NdeI-BamHI fragment by reverse transcription/PCR of total HeLa
is the role of Tra2 proteins? In our experiments, high cell RNA. To express HTra2a in E. coli the fragment was inserted
concentrations of purified SR proteins or ASF/SF2 (600 into pET14b (Novagen). After transfer to Bluescript KSII (Stra-
nM) were required to activate A3-dependent splicing in tagene), the cDNA was inserted as an XbaI-BamHI fragment into
the baculovirus expression vector pVL1392 (Pharmingen). To expressS100. Such high concentrations are unlikely to reflect
HTra2aDRSN (see below) in E. coli the Tra2a cDNA lacking codingphysiological conditions, as the concentrations of indi-
sequences upstream of the single EcoRII site was subcloned intovidual SR proteins in our HeLa NE are less than 50
pET14b. The full-length cDNA of human Tra2b was isolated from a
nM (R. T. and J. L. M., unpublished data). Under more human brain cDNA library using the previously obtained rat cDNA
physiological conditions, as in ourassays using NE, both (Matsuo et al., 1995) as a probe. The coding region was cloned as
human Tra2 proteins activated splicing in a sequence- an NdeI-BamHI PCR fragment into pET14b for the bacterial expres-
sion of HTra2b and eventually transferred to pFASTBAC1 for thespecific manner and were significantly more effective
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generation of a recombinant baculovirus using the BAC-TO-BAC XbaI (A3) or AluI (B3). Competitor RNAs were prepared by T7 tran-
scription of previously described template plasmids (Tacke andexpression system (GIBCO BRL). To express GST-Tra2b the coding
region was inserted blunt into the BamHI site of pGEX-2T (Phar- Manley, 1995; Tacke et al., 1997) linearized with XbaI andquantitated
by trace-labeling with (a32P)-GTP in parallel transcription reactions,macia).
assuming that transcription efficiency was the same in the presence
and absence of the labeled nucleotide. In vitro splicing was per-Purification of Recombinant Proteins
formed essentially as described (Tacke and Manley, 1995). For com-His-tagged recombinant proteins were expressed in BL21, purified
petition assays, competitor RNA was added together with the sub-under denaturing conditions by Ni21 agarose chromatography, and
strate to the splicing reaction. To relieve competition, Tra2 or SRrenatured by dialysis (Tacke and Manley, 1995). GST-tagged pro-
proteins were added last.teins were expressed in JM101 and purified under nondenaturing
conditions by glutathione agarose chromatography as described
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